AKIN GUMP STRAUSS HAUER & FELD for OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
The Innovation Act (H.R. 9); Helping Families in Mental Health Crisis Act (H.R. 2646); Mental Health Reform Act of 2015 (H.R. 1945); Mental Health Awareness and Improvement Act (S. 1893).
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEIDE BAJNRAUH | — |
| JOHN JONAS | — |
| RICHARD THOMPSON | — |
| ELI TOMAR | — |
| MATTHEW TODD TUTEN | — |
Health Issues HCR
Drug Pricing legislation introduced in the 116th Congress; P.L. 115-271, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act implementation; Contract Year (CY) 2020 Medicare Advantage and Part D Drug Pricing Proposed Rule (CMS-4180-P).
| Lobbyist | Covered position, as disclosed |
|---|---|
| LOUIS AGNELLO | — |
| HEIDE BAJNRAUH | — |
| JOHN JONAS | — |
| RICHARD THOMPSON | — |
| MATTHEW TODD TUTEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.